2-Amino-5-cyclohexylpyrimidin | 73549-64-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Amino-5-cyclohexylpyrimidin
• 英文别名: 5-Cyclohexylpyrimidin-2-amine
• CAS: 73549-64-1
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: OXBJITNIEIJQGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-Cyclohexyl-2-ethoxyethylen 在 sodium ethanolate 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 10.0h， 生成 2-Amino-5-cyclohexylpyrimidin
  参考文献：
  名称：

  Reichardt, Christian; Ferwanah, Abdel-Rahman; Pressler, Wilfried, Liebigs Annalen der Chemie, 1984, # 4, p. 649 - 679

  摘要：

  DOI：

文献信息

• REICHARDT, CH.;FERWANAH, ABDEL-RAHMAN;PRESSLER, W.;YUN, KYEONG-YEOL, LIEBIGS ANN. CHEM., 1984, N 4, 649-679
  作者：REICHARDT, CH.、FERWANAH, ABDEL-RAHMAN、PRESSLER, W.、YUN, KYEONG-YEOL

  DOI：——

  日期：——
• IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS
  申请人：Signal Pharmaceuticals, LLC

  公开号：EP2739751A1

  公开（公告）日：2014-06-11
• Kinase Inhibitor And Use Thereof
  申请人：XUANZHU PHARMA CO., LTD.

  公开号：US20160332989A1

  公开（公告）日：2016-11-17

  The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.
• US9796701B2
  申请人：——

  公开号：US9796701B2

  公开（公告）日：2017-10-24
• [EN] IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS<br/>[FR] IDENTIFICATION D'UN PROFIL D'EXPRESSION GÉNIQUE À TITRE DE BIOMARQUEUR PRÉDICTIF DE L'ÉTAT LKB1
  申请人：SIGNAL PHARM LLC

  公开号：WO2013019927A1

  公开（公告）日：2013-02-07

  Provided herein are methods for predicting the LKBl status of a patient or a biological sample, comprising the measurement of particular gene expression levels relative to a set of reference levels that represent the gene expression level of a biological wild-type sample without LKBl gene or protein loss or mutation and the gene expression level of a reference sample with LKBl gene or protein loss or mutation. Further provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by particular gene expression levels.